Brentuximab vedotin (Adcetris®). HTA ID: 21010

Assessment Status Rapid Review complete
HTA ID 21010
Drug Brentuximab vedotin
Brand Adcetris®
Indication In combination with cyclophosphamide [C], doxorubicin [H] and prednisone [P] (CHP) in combination for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
Assessment Process
Rapid review commissioned 24/03/2021
Rapid review completed 23/04/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin (Adcetris®)  compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations, December 2022.